Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.

Literature DB >> 33375215

Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.

Dipnarine Maharaj¹, Gayathri Srinivasan¹, Maria M Abreu², Meng-Wei Ko³, Anahid Jewett³, Jacqueline Gouvea¹.

Abstract

Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-aged female patient with poor prognosis unmutated IGHV CLL achieved cytogenetic and molecular remission with minimal adverse events following six cycles of low dose recombinant human IL-2 (rIL-2) in combination with low dose targeted venetoclax. Personalized low dose rIL-2 in combination with either lenalidomide or venetoclax mediates natural killer stimulation and is an effective non-toxic immunotherapy administered in the outpatient setting for poor prognosis CLL.

Entities: CellLine Chemical Disease Gene Species

Keywords: cancer treatment; chronic lymphocytic leukemia; immunotherapy; interleukin-2; natural killer cells

Mesh：

Substances：

Year: 2020 PMID： 33375215 PMCID： PMC7822209 DOI： 10.3390/cells10010010

Source DB: PubMed Journal: Cells ISSN： 2073-4409 Impact factor: 6.600

38 in total

1. Disease-specific complications of chronic lymphocytic leukemia.

Authors: Claire Dearden
Journal: Hematology Am Soc Hematol Educ Program Date: 2008

Review 2. CD56bright natural killer (NK) cells: an important NK cell subset.

Authors: Aurélie Poli; Tatiana Michel; Maud Thérésine; Emmanuel Andrès; François Hentges; Jacques Zimmer
Journal: Immunology Date: 2009-04 Impact factor: 7.397

Review 3. Functions of natural killer cells.

Authors: Eric Vivier; Elena Tomasello; Myriam Baratin; Thierry Walzer; Sophie Ugolini
Journal: Nat Immunol Date: 2008-05 Impact factor: 25.606

4. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus.

Authors: Xiao-Song He; Monia Draghi; Kutubuddin Mahmood; Tyson H Holmes; George W Kemble; Cornelia L Dekker; Ann M Arvin; Peter Parham; Harry B Greenberg
Journal: J Clin Invest Date: 2004-12 Impact factor: 14.808

5. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

Authors: D J DiLillo; J B Weinberg; A Yoshizaki; M Horikawa; J M Bryant; Y Iwata; T Matsushita; K M Matta; Y Chen; G M Venturi; G Russo; J P Gockerman; J O Moore; L F Diehl; A D Volkheimer; D R Friedman; M C Lanasa; R P Hall; T F Tedder
Journal: Leukemia Date: 2012-07-13 Impact factor: 11.528

6. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Authors: Iris de Weerdt; Tom Hofland; Renate de Boer; Johan A Dobber; Julie Dubois; Denise van Nieuwenhuize; Mehrdad Mobasher; Fransien de Boer; Mels Hoogendoorn; Gerjo A Velders; Marjolein van der Klift; Ester B M Remmerswaal; Frederike J Bemelman; Carsten U Niemann; Sabina Kersting; Mark-David Levin; Eric Eldering; Sanne H Tonino; Arnon P Kater
Journal: Blood Adv Date: 2019-09-10

1. A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia.

Authors: Han Gong; Heng Li; Qin Yang; Guangxiong Zhang; Hong Liu; Zekang Ma; Hongling Peng; Ling Nie; Xiaojuan Xiao; Jing Liu
Journal: Biomed Res Int Date: 2022-07-06 Impact factor: 3.246

1 in total

Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.

1. Disease-specific complications of chronic lymphocytic leukemia.

Review 2. CD56bright natural killer (NK) cells: an important NK cell subset.

Review 3. Functions of natural killer cells.

4. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus.

5. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

6. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

7. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.

Review 8. Role of Distinct Natural Killer Cell Subsets in Anticancer Response.

Review 9. Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.

10. Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL).

1. A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia.